MedTrace Logo

Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™

NCT01500486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2016-11-17

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this study is to evaluate ease of injection of growth hormone in patients using Norditropin NordiFlex® with NordiFlex PenMate™. Convenience and tolerability of NordiFlex PenMate™ - an automatic injection and a needle hiding device - is also evaluated.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Delivery Systems

Interventions

DEVICE

NordiFlex PenMate™

Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Germany
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01500486 on ClinicalTrials.gov